Prime Medicine vs Stipple Bio
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-2026. $3.5B+ BMS collaboration. CGD Phase 1 showing rapid function restoration after single infusion.
About
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable of making all 12 possible base-pair changes, small insertions, and deletions in DNA without double-strand breaks. The company has $191 million in cash runway into 2027, INDs planned for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD) in 2026, and a $55 million upfront collaboration with Bristol Myers Squibb worth up to $3.5 billion in milestones.
Precision oncology company emerged from stealth Apr 2026 with $100M oversubscribed Series A co-led by RA Capital and a16z Bio; Pointillist platform identifies novel tumor-specific epitopes for antibody-drug conjugates beyond existing ADC targets.
About
Stipple Bio is a precision oncology company that emerged from stealth in April 2026 with a $100 million oversubscribed Series A. The round was co-led by RA Capital Management, Andreessen Horowitz Bio+Health, and Nextech, with additional participation from GV and Emerson Collective — a top-tier syndicate that signals strong scientific conviction in the platform.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.